

# Epidemiology of Rheumatoid Arthritis in Korea

Hyounyoung Kim, M.D., M.S., Yoon-Kyoung Sung, M.D., Ph.D., MPH

Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by symmetrical involvement of the joints, associated extra-articular manifestations and functional disability. In Korea, several epidemiologic studies reporting prevalence and incidence rates of RA have been conducted using large databases such as claims databases, national surveys, prospective cohort databases or electronic health records; according to these data sources, the estimated prevalence ranged from 0.27% to 1.85%. The prevalence of extra-articular manifestations such as interstitial lung disease (ILD) and Sjögren's syndrome (SS) were also reported, but an issue of external validity of the study results persisted. In this review, we detail the epidemiology of Korean RA patients, focusing on the prevalence of RA and the frequency of systemic extra-articular manifestations including ILD and SS reported in previous studies. In addition, we discuss the current methodological issues which are inherent in Korean epidemiologic studies for patients with RA with understanding of the characteristics of each database. (**J Rheum Dis 2021;28:60-67**)

**Key Words.** Rheumatoid arthritis, Epidemiology, Comorbidity, Data sources

## INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by symmetrical involvement of the peripheral joints, associated extra-articular manifestations, functional disability and increased mortality if treated inadequately. RA is present worldwide, with an estimated prevalence of 0.5% to 2%, and both the incidence and prevalence of RA are two to three times greater in females than males [1].

In the past two decades, paradigm shifts for the diagnosis and management of RA have been revolutionised by a greater understanding of the pathogenic mechanisms and the development of new targeted therapies. Serum anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) play a role as prognostic biomarkers as they are routinely checked in patients with suspected RA. According to the profiles of the presence or absence of autoantibodies (immunoglobulin M RF and/or ACPAs), the disease can be classified into the categories of sero-

positive RA and seronegative RA, respectively [2]. Studies on RA have highlighted new disease-associated genes and environmental factors and explained the pathogenesis of RA clearly. This progress contributes to develop targeted biologic agents and small-molecule inhibitors. Much of this work has enabled the expansion of treatment options and earlier treatment intervention.

Although the hallmark clinical manifestation of RA is painful inflammatory arthritis, extra-articular manifestations contribute to excess morbidity and mortality [3]. Rheumatoid nodules and osteoporosis are relatively common manifestations, and systemic manifestations such as vasculitis, Sjögren's syndrome (SS) or pulmonary fibrosis also occasionally appear. However, the frequency of extra-articular manifestations in RA differs between countries, and their incidence and prevalence rates vary according to study design [4]. In this review, we detail the epidemiology of Korean patients with RA, focusing on its prevalence and the frequency of systemic extra-articular manifestations, such as interstitial lung disease (ILD)

Received : March 14, 2021, Accepted : March 18, 2021

Corresponding to : Yoon-Kyoung Sung  <http://orcid.org/0000-0001-6691-8939>

Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. E-mail : [sungyk@hanyang.ac.kr](mailto:sungyk@hanyang.ac.kr)

Copyright © 2021 by The Korean College of Rheumatology.

This is an Open Access article, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

and SS, reported in previous studies. In addition, we discuss the methodological issues that exist in Korean epidemiologic studies for patients with RA.

## MAIN SUBJECTS

### Prevalence and incidence rate of RA in Korea

#### 1) Prevalence of RA

Seven studies have reported the prevalence of RA in Korea [5-11]. The prevalence of RA in Korea ranges from 0.27% to 1.85% and the female-to-male ratio is between 2.7:1 and 13.5:1 (Table 1). The prevalence of RA in each Korean study is different according to the methodology as well as the case definition of RA employed; however, all of the included studies employed a cross-sectional design in a population-based cohort investigation. Interestingly,

the prevalence was less than 0.5% as the studies were performed based on national health insurance (NHI) claims data, though the prevalence exceeds 1.4% if the case definition of RA was defined by patient-reported questionnaire.

#### 2) Incidence of RA

There were three studies found that assessed the incidence of RA in Korea [7,8,12], all of which used the NHI claims database; two included all beneficiaries of national healthcare insurance and the third study considered a cohort of one million Koreans based on the NHI claims database. All three studies used an operational definition for RA, including diagnostic codes of RA (M05 with or without M06) and any disease-modifying antirheumatic drug (DMARD) prescription. Among them, two studies were performed by our group and the latter one was an updated version of the first study. According to this study,

**Table 1.** Epidemiologic studies of the prevalence of patients with RA in Korea

Study	Prevalence (%)	Female/ Male ratio	Study period (yr)	Diagnostic criteria	Number of study population	Age of study population
Hur et al. 2008 [5]	1.85% (95% CI 1.66~2.04)	2.7	2005	Questionnaire	33,805	≥ 19
Park et al. 2003 [6]	1.40% (95% CI 0.68~2.17)	13.5	2000	ACR 1987 revised criteria	983	Mean age 49.9±14.0
Won et al. 2018 [7]	0.32%	3.6	2009~2012	Operational definition	All beneficiaries	19~99
Sung et al. 2013 [8]	0.27% (95% CI 0.26~0.28)	3.7	2007~2009	Operational definition	All beneficiaries	≥ 16
Kwon et al. 2012 [9]	1.45% (95% CI 1.27~1.64)	3.7	2007~2009	Questionnaires	17,311	≥ 19
Kim et al. 2020 [10]	0.19% (95% CI 0.188~0.189)	4.3	2012~2016	Operational definition (seropositive only)	All beneficiaries	19~99
Jeong et al. 2017 [11]	1.50%	3.3	2010~2012	Questionnaires	17,887	≥ 19

RA: rheumatoid arthritis, CI: confidence interval, ACR: American college for rheumatology.

**Table 2.** Epidemiologic studies of the incidence of patients with RA in Korea

Study	Incidence (PY or persons)	Female/ Male ratio	Study period (yr)	Diagnostic criteria	Number of study population	Age of study population
Won et al. 2018 [7]	28.5/100,000 PY	3.5	2010	Operational definition	All beneficiary	19~99
Sung et al. 2013 [8]	42.0/100,000 persons (95% CI 29.3~54.7)	3.4	2008	Operational definition	All beneficiary	≥ 16
Choi et al. [12]	16.5/100,000 PY Seropositive RA	3.4	2002~2013	Operational definition (seropositive only)	1 million cohort	All ages

RA: rheumatoid arthritis, CI: confidence interval, PY: person-year.

the incidence of Korean patients with RA was 28.5/100,000 person-years and the female-to-male ratio was about 3.5 [7,8] (Table 2). When compared with the incidence of RA in East Asian countries, which ranges from 15.8 to 42.0 per 100,000 people [13-18], the incidence rate of RA patients in Korea was comparable. The other study performed by Choi et al. [12] was not a definite epidemiologic study, but the authors selected the incidence cases of RA between 2002 and 2013 to calculate the mortality, disability and healthcare expenditures of patients with RA. However, they include only seropositive RA patients, and their incidence rate was only 16.5/100,000 person-years [12].

### 3) Data sources of epidemiologic study for RA in Korea

Using the claims data, we could estimate healthcare utilization and healthcare costs macroscopically, and assess distribution of certain diseases, treatment patterns, as well as clinical outcome of specific drug and disease in real world. Korea utilized universal mandatory health insurance system which offers claims data characterised as an enormous, detailed amount of information. Even though it represents the status of a nationwide large population, errors such as inaccurate diagnosis codes may occur when it is utilized in epidemiologic studies. Park et al. [23] reported inconsistency in major and minor diagnoses of RA in medical records compared to the claims databases as 58.6% and 38.4%. A patient selection according to the diagnostic code is not sufficient enough to identify overall RA patients in claims databases [19-23].

Several years ago, we compared the diagnostic validity between several algorithms for identifying RA patients in the NHI claims database [24]. We found that patients having at least one claim in a year with a prescription of biologics or any DMARD under an RA code had high sensitivity and accuracy rates and a positive predictive value (PPV) of 96.46%, 90.33% and 92.35%, respectively, when the fulfilment of more than four of the 1987 American College of Rheumatology (ACR) classification criteria for RA was adopted as the gold standard. There is a limitation in the possibility of a false-negative result when using our algorithm; RA patients without any history of DMARDs might be excluded if they had a successful treatment response or were pregnant. However, our approach was rational because a conservative approach is generally acceptable for estimating the prevalence, incidence or outcomes in epidemiologic studies.

Electronic health records (EHRs) are generated by clini-

cian and it contains a comprehensive information for patient's health state and treatment. EHRs present mixtures of structured information including diagnoses, physical examinations, radiologic/laboratory test results or management as well as unstructured notes. Although these data contain more detailed clinical information than a claims database in general, data are often inaccurately coded with substantial missing and even informatively missing information [25]. The claims and EHR records of each person are started when they participate in a health system or are first treated under a health system and stop when they leave the health system or dies. Claims data could define a particular population at a certain time point, while EHR data are more complicated to use to identify the population under specific care of interest at any point in time. These censoring issues may affect the estimation of the prevalence and incidence of chronic diseases.

Another data source is the Korea National Health and Nutrition Examination Survey (KNHANES), which is a nationwide cross-sectional study of selected sample of the Korean population. This survey employed a stratified multistage design based on age, sex and residence geographic area [19,21-23] and provides a presentative and cost-efficient method to collect clinical data in the form of self-report questionnaires.

Although EHRs are restricted for the latest records and under-reporting of conditions before admission [25,26], they provide a mixture of primary data including comprehensive information of both patient self-reporting and physicians' documentation [25-27]. Self-reports and EHR reviews are still the most common methods of assessment due to their availability, efficiency and relatively low cost [28]. Several studies have indicated that the corporate use of comorbidity data-collection methods using both sources is required to analyse or predict certain health outcomes [25,26,29,30]. However, self-reports and EHRs is still inconsistent. Previous studies have compared the two data sources in terms of assessing medical history, medication use and other risk factors [9,11,19,28]. The agreement level varied from high to low depending upon the variables in the comparison and the study populations [26-31].

## Seropositivity of Korean patients with RA

### 1) Proportions of seronegative RA

The identification of RF and ACPAs has contributed to

the classification of the subgroups of seropositive and seronegative RA, respectively [32]. Previously, seropositivity was defined in terms of RF, especially as we used the 1987 ACR classification criteria. A seronegative status means that tests do not show the presence of RF. Following the introduction of the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA, the meaning of a seronegative test result for RA changed to be when a person tests negative for both RF and ACPA. While most patients positive for ACPAs are also positive for RF, the RF antibody can occur in patients with many other conditions, including viral hepatitis and other rheumatic diseases. Conversely, ACPA is more specific for RA and is becoming the preferred test for making this distinction. Seropositive RA patients present certain genetic and environmental risk factors in common and have been observed to have more severe clinical presentations [33,34]. Seronegative RA has not been fully assessed, but evidence of genetic associations for ACPA-negative RA has been offered [35].

The largest Korean multicentre cohort, the Korean Observational Study Network for Arthritis (KORONA) database, had enrolled 4,721 RA patients who fulfilled the 1987 ACR classification criteria as of December 2010 [36]. This group had a mean age of  $54.25 \pm 12.19$  years and included 4,023 women (85.21%). Their RF positivity and ACPA positivity rates were 86.8% (4,098/4,719) and 83.9% (3,018/3,599), respectively. Meanwhile, recent data from the Korean College of Rheumatology Biologics (KOBIO) registry, a nationwide biologics registry, shows that RF positivity and ACPA positivity rates in RA patients on targeted therapy were 87.0% and 86.3%, respectively [37]. Among conventional synthetic DMARD users, RF positivity and ACPA positivity rates were

slightly lower at 83.9% and 85.3%. This suggested that confounding by indication is another important issue in the observational-type study.

Another important point to consider when conducting analysis based on claims data is the inclusion of inaccurate diagnostic codes (unpublished data, Table 3). We selected all RA patients in Korea according to three definitions. If we selected RA patients with diagnostic codes only, the numbers of seropositive RA (M05) and seronegative RA (M06) cases in 2016 were 150,058 and 688,053, respectively. However, after applying the operational definition of a diagnostic code with any DMARD, the numbers of seropositive and seronegative RA cases decreased to 103,083 and 74,038, respectively. This shows that many of the patients with RA diagnostic codes are not taking any DMARDs and this phenomenon is more pronounced in seronegative RA patients. Patients who are negative for RF and ACPA may also have another form of inflammatory arthritis—such as psoriatic arthritis or a spondyloarthropathy. A definition of RA with diagnostic codes and inclusion in the rare and intractable disease registration (RIDR) program is most specific for RA patients since registration in the RIDR program by a physician is required. Therefore, the latter definition is useful for outcomes and pharmaco-economic studies assessing definite RA patients. The limitation of this definition is that it would not be applicable to seronegative RA patients because only seropositive RA patients are able to be registered in the RIDR program in Korea.

## 2) Disease severity of seronegative RA

Until now, patients with seropositive RA are considered to be at greater risk for severe RA, but these tests could not accurately predict the prognosis of RA in each patient.

**Table 3.** Proportions of seropositive and seronegative RA patients using claims database based on their definitions

Year	Seropositive RA			Seronegative RA		
	Diagnostic code*	Diagnostic code with RIDR program <sup>†</sup>	Operational definition <sup>‡</sup>	Diagnostic code*	Diagnostic code with RIDR program <sup>†</sup>	Operational definition <sup>‡</sup>
2012	112,983 (224.4)	70,276 (139.6)	79,337 (157.6)	646,459 (1,284.1)	NA	69,709 (138.5)
2016	150,058 (293.6)	96,330 (188.5)	103,083 (201.7)	688,053 (1,346.3)	NA	74,038 (144.9)

Values are presented as number (prevalence). Prevalence presented as n/100,000 persons. RA: rheumatoid arthritis, NA: not applicable, RIDR: Rare Intractable Disease registration, ICD: International Classification of Diseases, DMARD: disease-modifying antirheumatic drug. \*Estimated prevalence by ICD-10 diagnostic codes. <sup>†</sup>Estimated prevalence by diagnostic codes which was applicable to RIDR program. <sup>‡</sup>Operational definition of RA was confined to prescription of any DMARDs under specific diagnostic codes (M05.X) at least once for each calendar year.

Furthermore, along with seropositive patients having a higher risk of severe disease, they tend to have more extra-articular manifestations than those who are seronegative. Generally, the clinical presentation and prognosis of seronegative RA have been reported as less severe than those for seropositive RA, although the literature is still in conflict [2]. Recent studies have suggested that seronegative patients to have greater disease activity than seropositive patients when evaluated by ultrasonography scores for joints (median 55 vs. 25,  $p < 0.001$ ) and tendons (median 3 vs. 0,  $p < 0.001$ ), by the number of swollen joints (median 17 vs. 8,  $p < 0.001$ ), by the Disease Activity Score (mean 3.9 vs. 3.4,  $p = 0.03$ ) and by the Physician's Global Assessment (mean 49.1 vs. 38.9,  $p = 0.006$ ) [38]. It implicated that the high number of involved joints required for seronegative patients to fulfil the 2010 ACR/EULAR classification criteria for RA, which led to redefining the patient population by enacting greater weights of serology [39]. In comparison with the 1987 criteria [40], more number of seropositive RA with a milder disease activity could be classified as having RA.

In a Korean study, among the 241 RA patients who were naive to any DMARDs according to the 1987 ACR criteria or the 2010 ACR/EULAR criteria [41], seronegative patients totalled 16.6% and had more severe disease activity and similar radiographic damage relative to seropositive RA patients.

When we consider the differences between our experiences and the evidence, further studies are necessary involving seronegative RA patients to identify their genetic risk, drug responses to biologic DMARDs and the long-term prognosis relative to seropositive patients.

## **Prevalence of comorbidities of Korean patients with RA**

### **1) Prevalence of interstitial lung disease in patients with RA**

In Korea, several studies were performed to identify the prognosis and outcomes of ILD in patients with RA. ILD itself increased mortality of RA patients [42], and age over 65 at the time of ILD diagnosis, Usual interstitial pneumonia pattern [43], and higher Kerbs von den Lungen-6 (KL-6) level [44] were revealed as poor prognostic factors for survival of RA-ILD patients. However, it is scarce that the prevalence of ILD is identified among representative patients with RA in Korea. A single-centre

study retrospectively reviewed EHRs and computed tomography (CT) scans and reported the prevalence of ILD in 507 patients with RA to be 12.6% [45]. It is worth noting that, although the presence of ILD was confirmed by CT scan, there was a possibility of indication bias for CT scan among RA patients.

In a multicentre study using the KORONA database, we reported the prevalence of ILD. Among 3,555 patients with RA whose chest X-rays (CXRs) or CT scans were taken within one year of enrolment, 64 (1.8%) patients had ILD. A comparison of the prevalence of ILD detected by CXR and chest CT revealed an obvious difference; of those RA patients for whom only CXR results were accessible ( $n = 3,311$ ; 93.1% of the total 3,555 patients), 1.2% had ILD. However, 9.8% were found to have ILD among the patients whose chest CT scans were available ( $n = 244$ ; 6.9% of the total 3,555 patients). This result suggests both the possibility of underestimation of the prevalence of ILD by CXR and the potential confounding by indication for chest CT in calculating the prevalence of ILD in RA patients [42].

Recently, a study group in the United States developed and validated claims-based algorithms to identify ILD in patients with RA using the Medicare database [46] and found that ILD was present or later developed in nearly 5% of patients in this nationwide study of older patients with RA [47]. This nationwide study's use of claims data to identify the impact of ILD on the outcomes of RA patients was meaningful and valuable. However, the remaining unmeasured confounders and the low PPV were problematic, which is similarly true for the use of Korean claims data. Further validation research is also required in Korea.

### **2) Prevalence of Sjögren's syndrome in patients with RA**

A recent Korean cross-sectional study in a single centre showed that 72 (8.7%) of 827 RA patients were diagnosed as having SS by a rheumatologist, although 60 patients (7.3%) fulfilled the 2002 American-European Consensus Group (AECG) classification criteria for SS. Fifty-two patients (6.3%) and 56 patients (6.8%) satisfied the 2012 ACR and 2016 ACR/EULAR classification criteria [48]. The prevalence rate of SS among RA patients in this study was higher than was reported in former studies conducted in Denmark (3.6%) and Turkey (5.3%) and lower than that reported in the United States (10.3%), China (14.5%) and Italy (17.5%) [49-54].

Designs of the study and case definitions of SS have affected estimates of the SS prevalence in RA patients. In terms of disease definition, the 2002 AECG criteria were utilized in the American and Chinese studies, while the studies in Denmark, Italy and Turkey applied clinical diagnoses.

Epidemiologic study of SS in patients with RA is more complex than studies for each disease. Frequent change in classification criteria and the low performance rate of labial salivary gland biopsy and ophthalmologic examination interferes in the estimation of the exact prevalence of SS. We can also use claims database in epidemiologic research for SS as a primary or secondary form of information. However, a more novel operational definition with high PPV is needed for selecting the exact cases of SS in Korea.

## CONCLUSION

Various epidemiologic studies involving Korean patients with RA have been conducted using multiple databases such as a claims database, KNHANES, prospective cohort database and EHRs. We should be aware of the strengths and limitations of each database and select the appropriate data source to accurately calculate the prevalence and incidence rates of RA and related comorbidities. Further methodological revision for effective epidemiologic study not just of RA but other rheumatic diseases is needed.

## ACKNOWLEDGMENTS

This research was supported by a grant from the Patient-centred Clinical Research Coordinating Centre funded by the Ministry of Health and Welfare, Republic of Korea (grant nos. HI19C0481 and HC19C0052).

## CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

## AUTHOR CONTRIBUTIONS

Y.K.S. was involved in conception and design of study. Y.K.S. and H.Y.K. were contributed to acquisition, analysis, and interpretation of data. All authors were involved in drafting and revising the manuscript critically for important intellectual content and final approval of the ver-

sion to be published.

## REFERENCES

1. Brown KK. Rheumatoid lung disease. *Proc Am Thorac Soc* 2007;4:443-8.
2. Ajeganova S, Huizinga TW. Rheumatoid arthritis: seronegative and seropositive RA: alike but different? *Nat Rev Rheumatol* 2015;11:8-9.
3. Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. *J Rheumatol* 2011; 38:983-9.
4. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. *Maedica (Bucur)* 2010;5:286-91.
5. Hur NW, Choi CB, Uhm WS, Bae SC. The prevalence and trend of arthritis in Korea: results from Korea National Health and Nutrition Examination Surveys. *J Korean Rheum Assoc* 2008;15:11-26.
6. Park NG, Kim WK, Shin DH, Choi YM, Lee YJ, Lee EB, et al. Prevalence of osteoarthritis and rheumatoid arthritis in two communities in Korea. *J Korean Rheum Assoc* 2003;10: 151-7.
7. Won S, Cho SK, Kim D, Han M, Lee J, Jang EJ, et al. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. *Rheumatol Int* 2018;38:649-56.
8. Sung YK, Cho SK, Choi CB, Bae SC. Prevalence and incidence of rheumatoid arthritis in South Korea. *Rheumatol Int* 2013;33:1525-32.
9. Kwon JM, Rhee J, Ku H, Lee EK. Socioeconomic and employment status of patients with rheumatoid arthritis in Korea. *Epidemiol Health* 2012;34:e2012003.
10. Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. *Semin Arthritis Rheum* 2020; 50:526-33.
11. Jeong H, Baek SY, Kim SW, Eun YH, Kim IY, Kim H, et al. Comorbidities of rheumatoid arthritis: results from the Korean National Health and Nutrition Examination Survey. *PLoS One* 2017;12:e0176260.
12. Choi IA, Lee JS, Song YW, Lee EY. Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: a nationwide population-based study. *PLoS One* 2019;14:e0210471.
13. Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. *Int J Rheum Dis* 2017;20:839-45.
14. Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. *Clin Exp Rheumatol* 2012;30:358-63.
15. Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. *Rheumatol Int* 2013;33:355-60.
16. See LC, Kuo CF, Chou IJ, Chiou MJ, Yu KH. Sex- and age-specific incidence of autoimmune rheumatic diseases in

- the Chinese population: a Taiwan population-based study. *Semin Arthritis Rheum* 2013;43:381-6.
17. Yang DH, Huang JY, Chiou JY, Wei JC. Analysis of socioeconomic status in the patients with rheumatoid arthritis. *Int J Environ Res Public Health* 2018;15:1194.
  18. Chiu YM, Lu YP, Lan JL, Chen DY, Wang JD. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: a nationwide cohort followed up from 2003 to 2016. *Arthritis Rheumatol* 2020 Dec 8 [Epub]. DOI: 10.1002/art.41597.
  19. Losina E, Barrett J, Baron JA, Katz JN. Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. *J Clin Epidemiol* 2003;56:515-9.
  20. 2019 National Health Insurance Statistical Yearbook. National Health Insurance Statistics [Internet]. Wonju: National Health Insurance Service [cited 2021 Mar 9]. Available from: <https://www.nhis.or.kr/nhis/together/wbhaec06300m01.do?mode=view&articleNo=10802543&article.offset=0&articleLimit=10>.
  21. Kim JY KH, Im JH. Development of risk adjustment and prediction methods for care episodes using National Health Insurance Database [Internet]. Seoul: Health Insurance Review & Assessment Service, 2007 [cited 2021 Mar 9]. Available from: [https://scholar.google.com/scholar\\_lookup?title=Development%20of%20risk%20adjustment%20and%20prediction%20methods%20for%20care%20episodes%20using%20National%20Health%20Insurance%20Database&publication\\_year=2007&author=Kim%2CJY&author=Kim%2CHY&author=Im%2CJH](https://scholar.google.com/scholar_lookup?title=Development%20of%20risk%20adjustment%20and%20prediction%20methods%20for%20care%20episodes%20using%20National%20Health%20Insurance%20Database&publication_year=2007&author=Kim%2CJY&author=Kim%2CHY&author=Im%2CJH).
  22. Ko MJ, Han JT, Lee AK, Kim MK, Park SH. Health checkup examinees cohort establishment: the development of assessment [Internet]. Seoul: National Health Insurance Corporation, 2008 [cited 2021 Mar 9]. Available from: <https://www.nhis.or.kr/nhis/together/wbhaec07800m01.do?mode=view&articleNo=106556>.
  23. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Improving the validity of health insurance claim data. Seoul: Seoul National University College of Medicine, 2003, 223 p.
  24. Cho SK, Sung YK, Choi CB, Kwon JM, Lee EK, Bae SC. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. *Rheumatol Int* 2013;33:2985-92.
  25. Ahn GY, Cho SK, Kim D, Choi CB, Lee EB, Bae SC, et al. Agreement of major diagnosis and comorbidity between self-reported questionnaire and medical record review in patients with rheumatic disease. *J Rheum Dis* 2016;23:348-55.
  26. Corser W, Sikorskii A, Olomu A, Stommel M, Proden C, Holmes-Rovner M. Concordance between comorbidity data from patient self-report interviews and medical record documentation. *BMC Health Serv Res* 2008;8:85.
  27. Tisnado DM, Adams JL, Liu H, Damberg CL, Chen WP, Hu FA, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? *Med Care* 2006;44:132-40.
  28. Byles JE, D'Este C, Parkinson L, O'Connell R, Treloar C. Single index of multimorbidity did not predict multiple outcomes. *J Clin Epidemiol* 2005;58:997-1005.
  29. Kvien TK, Glennäs A, Knudsrød OG, Smedstad LM. The validity of self-reported diagnosis of rheumatoid arthritis: results from a population survey followed by clinical examinations. *J Rheumatol* 1996;23:1866-71.
  30. Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records. *Neth J Med* 1999;55:177-83.
  31. Simpson CF, Boyd CM, Carlson MC, Griswold ME, Guralnik JM, Fried LP. Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. *J Am Geriatr Soc* 2004;52:123-7.
  32. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. *Lancet* 2009;373:659-72.
  33. Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. *Ann Rheum Dis* 2010;69:345-51.
  34. Han B, Diogo D, Eyre S, Kallberg H, Zhernakova A, Bowes J, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. *Am J Hum Genet* 2014;94:522-32.
  35. Daha NA, Toes RE. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? *Nat Rev Rheumatol* 2011;7:202-3.
  36. Sung YK, Cho SK, Choi CB, Park SY, Shim J, Ahn JK, et al. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. *Semin Arthritis Rheum* 2012;41:745-51.
  37. Min HK, Kim HR, Lee SH, Shin K, Kim HA, Park SH, et al. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry. *Clin Rheumatol* 2021 Feb 12 [Epub]. DOI:10.1007/s10067-021-05613-x.
  38. Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, et al. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. *Ann Rheum Dis* 2017;76:341-5.
  39. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569-81.
  40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
  41. Choi S, Lee KH. Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study. *PLoS One* 2018;13:e0195550.
  42. Kim D, Cho SK, Choi CB, Choe JY, Chung WT, Hong SJ, et al. Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. *Rheumatol Int* 2017;37:1735-45.
  43. Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis.

- Korean J Intern Med 2019;34:434-41.
44. Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. *PLoS One* 2020;15:e0229997.
  45. Kim JW, Lee H, Hwang JH, Park SH, Lee HS, Kim SK, et al. Factors associated with airway disease and interstitial lung disease in rheumatoid arthritis. *J Rheum Dis* 2016;23:101-8.
  46. Cho SK, Doyle TJ, Lee H, Jin Y, Tong AY, Ortiz AJS, et al. Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis. *Semin Arthritis Rheum* 2020;50:592-7.
  47. Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. *Rheumatology (Oxford)* 2021 Jan 18 [Epub]. DOI:10.1093/rheumatology/keaa836.
  48. Kim H, Cho SK, Kim HW, Han J, Kim Y, Hwang KG, et al. The prevalence of Sjögren's syndrome in rheumatoid arthritis patients and their clinical features. *J Korean Med Sci* 2020;35:e369.
  49. Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. *Rheumatology (Oxford)* 2015;54:816-20.
  50. He J, Ding Y, Feng M, Guo J, Sun X, Zhao J, et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. *Rheumatology (Oxford)* 2013;52:1084-9.
  51. Haga HJ, Naderi Y, Moreno AM, Peen E. A study of the prevalence of sicca symptoms and secondary Sjögren's syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. *Int J Rheum Dis* 2012;15:284-8.
  52. Calgüneri M, Ureten K, Akif Oztürk M, Onat AM, Ertenli I, Kiraz S, et al. Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey. *Clin Exp Rheumatol* 2006;24:305-8.
  53. Cimmino MA, Salvarani C, Macchioni P, Montecucco C, Fossaluzza V, Mascia MT, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. *Rheumatol Int* 2000;19:213-7.
  54. Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. *J Rheumatol* 2008;35:995-1001.